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Abstract  
 Binary and ternary complexes derived from ligands containing 
Oxygen, suppler and Nitrogen as donor atoms with Pd2+ and Pt2+ ions were 
synthesized. The isolated solid complexes were characterized by elemental 
analyses and spectral (IR, 1H-NMR, mass spectrometry) measurements. The 
biological efficiency of the synthesized complexes on antitumor, 
antibacterial and antifungal was investigated. The results reveal that these 
complexes have strong affinity against the growth of bacteria and fungi. The 
mode of action may involve the formation of hydrogen bonding between the 
O and N donors and the active centers of the cell constituents, resulting in 
interference with the normal cell process. The biological results obtained 
were compared with that obtained using standard tetracycline as antibacterial 
and amphotericin B as antifungal. The complexes, PtL3L9 and PtL3L10, are 
considered as strong anticancer drugs, which have enhanced high biological 
activity. 
 
Keywords: Binary and ternary complexes; Pd and Pt complexes, 
Spectroscopic studies, Biological activity 
 
Introduction 
 Platinum-based drugs are widely used as anticancer agents with a 
broad range of antitumor activities. Cis-platin has a significant activity in 
ovarian, testicular, bladder, head and neck, and lung cancer, where it is most 
commonly used in combination with other drugs [1]. The resistance of tumor 
cells to cis-platin remains a major cause of treatment failure in cancer 
patients, while the high toxicity of cis-platin limits the dose that can be given 
to patients. Transition metal complexes of heterocyclic compounds 
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containing nitrogen as donor atoms such as pyridines;bi- and polypyridines, 
2-(2'-pyridyl)-benzimidazole, 2-pyrazinecarboxylic acid, 2-
pyrazinecarboxamide and 2-aminobenzimidazole; have a vital role in biology 
[5-8]. The aim of this work is to synthesize some binary and ternary Pd2+ and 
Pt2+ complexes with heterocyclic nitrogen donor ligands as well as selected 
ligands containing oxygen and/or sulfur donor atom. The biological activities 
for most of the complexes are studied. The cytotoxicity of three 
Pt2+complexes were also screened against two breast cancer cell lines (MCF7 
and T47D) and human liver carcinoma cell line (HepG2). 
 
Materials and Methods 
 Synthesis of binary Pd2+complexes 
 The reactions of 50 mL of K2[PdCl4](0.5 mmol) with 0.5 mmol of the 
ligands (L1-L5) dissolved in a minimum amount of EtOH in different ratios 
and temperatures as shown in Table (1). 
Table 1: 
The ligand Amount g 
Temp.; 
oC 
Time 
(min) Color 
2-aminobenzimidazole         (L1) 0.08 70 30 reddish-brown 
2-(2’-pyridyl)benzimidazole (L2) 0.10 RT immediately pale yellow 
2-pyrazinecarboxamide        (L3) 0.06 RT immediately brown 
2-pyrazinecarboxylic acid    (L4) 0.07 RT immediately yellow 
2-aminothiazole              (L5) 0.05 70 30 brown 
 
   Synthesis of ternary Pd2+ complexes 
 The reactions of 50 mL of K2[PdCl4] with two mixed ligands [L1 is 
one of them] (0.5 mmol of each ligand dissolved in a minimum amount of 
EtOH) in different ratio and temperature as shown in Table (2). 
Table 2: 
mixed ligands (L1) + L 
Amount 
g 
Temp.; 
oC 
Time 
(min) Color 
2-aminobenzimidazole (L1) + 
2-aminothiazole (L5) + Pd2+salt 
0.07 (L1) + 
0.05 (L5) 
70 30 reddish-brown needles 
2-aminobenzimidazole (L1) + 
urea (L7)  + Pd2+salt 
0.07 (L1) + 
0.03 (L7) 
70 30 reddish-brown  
2-aminobenzimidazole (L1) + 
thiourea (L8) + Pd2+salt 
0.07 (L1) + 
0.04 (L8) 
70 30 reddish-brown  
2-aminobenzimidazole (L1) + 
pyridine (L9) + Pd2+salt 
0.07 (L1) + 
(L5) 
RT immediately yellow 
2-aminobenzimidazole (L1) + 
bipyridine (L10) + Pd2+salt 
0.07 (L1) + 
0.08 (L10) 
RT immediately yellow 
 
 Table (3) represented the reactions of 50 ml (0.5 mmol) K2[PdCl4] 
with two mixed ligands, [L2 is one of them] (0.5 mmol of each ligand 
dissolved in minimum amount of EtOH) in different ratio and temperature. 
European Scientific Journal October  2014 edition vol.10, No.30 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
46 
Table 3. 
The mixed ligands (L2) + L 
Amount 
g 
Temp.; 
oC 
Time 
(min) Color 
2-(2’-pyridyl)benzimidazole (L2)+ 
2-aminothiazole (L5) + Pd2+salt 
0.19 (L2) + 
0.05 (L5) 
RT immediately buff 
2-(2’-pyridyl)benzimidazole (L2)+ 
urea (L7) + Pd2+salt 
0.1 (L2) + 
0.03(L7) 
RT immediately buff 
2-(2’-pyridyl)benzimidazole (L2)+ 
thiourea (L8) + Pd2+salt 
0.1 (L2) + 
0.04 (L8) 
RT immediately buff 
2-(2’-pyridyl)benzimidazole (L2)+ 
pyridine (L9) + Pd2+salt 
0.1 (L2) + 
0.5 ml (L5) 
70 30 Greenish-yellow 
2-(2’-pyridyl)benzimidazole (L2)+ 
bipyridine (L10) + Pd2+salt 
0.1 (L2) + 
0.08 (L10) 
RT immediately buff 
 
 Table (4) represent the reactions of 50 ml (0.5 mmol) [PdCl4]2-  with 
two mixed ligands, [L3 is one of them] (0.5 mmol of each ligand  dissolved in 
minimum amount of EtOH) in different ratio and temperature. 
Table 4. 
mixed ligands (L3) + L 
Amount 
g 
Temp.; 
oC 
Time 
(min) Color 
2-pyrazinecarboxamide (L3) + 
2-aminothiazole (L5) + Pd2+salt 
0.06 (L3) + 
0.05 (L5) 
70 30 dark brown 
2-pyrazinecarboxamide (L3) + 
urea (L7) + Pd2+salt 
0.06 (L3) + 
0.03 (L7) 
70 30 brown 
2-pyrazinecarboxamide (L3) + 
thiourea (L8) + Pd2+salt 
0.06 (L3) + 
0.04 (L8) 
RT immediately brown 
2-pyrazinecarboxamide (L3) + 
pyridine (L9) + Pd2+salt 
0.06 (L3) + 
0.5 ml (L5) 
RT immediately yellow 
2-pyrazinecarboxamide (L3) + 
bipyridine (L10) + Pd2+salt 
0.06 (L3) + 
0.08 (L10) 
70 30 yellow 
 
 Table (5) represent the reactions of 50 ml (0.5 mmol) [PdCl4]2-  with 
two mixed ligands, [L4 is one of them] (0.5 mmol of each ligand  dissolved in 
minimum amount of ethanol) in different ratio and temperature. 
Table 5. 
mixed ligands (L4) + L 
Amount 
g 
Temp.; 
oC 
Time 
(min) Color 
2-pyrazinecarboxylic acid (L4) + 
2-aminothiazole (L5) + Pd2+salt 
0.07 (L4) + 
0.05 (L5) 
70 30 orange 
2-pyrazinecarboxylic acid (L4) + 
urea (L7) + Pd2+salt 
0.07 (L4) + 
0.03(L7) 
70 30 yellow 
2-pyrazinecarboxylic acid (L4) + 
thiourea (L8) + Pd2+salt 
0.07 (L4) + 
0.04 (L8) 
RT Immediately red 
2-pyrazinecarboxylic acid (L4) + 
pyridine (L9) + Pd2+salt 
0.07 (L4) + 
0.5 ml (L5) 
70 30 yellow 
2-pyrazinecarboxylic acid (L4) + 
bipyridine (L10) + Pd2+salt 
0.07 (L4) + 
0.09 (L10) 
RT Immediately yellow 
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 Synthesis of binary Pt2+ Complexes 
 Table (6) represent the reactions of 50 ml (0.5 mmol) [PtCl4]2- with 
0.5 mmol ligands L1-L5 (dissolved in minimum amount of ethanol) in 
different ratio and temperature. 
Table 6. 
Ligand Amount g Temp.;oC Time(min) Color 
2-aminobenzimidazole(L1) + 
Pt2+salt 0.07 70 30 red 
2-(2’-pyridyl)benzimidazole (L2) + 
Pt2+salt 0.10 70 30 pale yellow 
2-pyrazinecarboxamide (L3) + 
Pt2+salt 0.06 70 30 brown 
2-pyrazinecarboxylic acid (L4) + 
Pt2+salt 0.07 70 30 orange 
2-aminothiazole (L5) + 
Pt2+salt 0.05 70 30 dark brown 
 
 Synthesis of ternary Pt2+ complexes 
 Table (7) represent the reactions of 50 ml (0.5 mmol) [PtCl4]2-  with 
two mixed ligands, [L1 is one of them] (0.5 mmol of each ligand  dissolved 
in minimum amount of ethanol) in different ratio and temperature. 
Table 7. 
mixed ligands (L1) + L 
Amount 
g 
Temp.; 
oC 
Time 
(min) Color 
2-aminobenzimidazole (L1) + 
urea (L7) + Pt2+salt 
0.07 (L1) + 
0.03 (L7) 
70 30 pale brown  
2-aminobenzimidazole (L1) + 
thiourea (L8) + Pt2+salt 
0.07 (L1) + 
0.04 (L8) 
70 30 brown  
2-aminobenzimidazole (L1) + 
pyridine (L9) + Pt2+salt 
0.07 (L1) + 
0.5 ml (L5) 
70 30 red 
2-aminobenzimidazole (L1) + 
bipyridine (L10) + Pt2+salt 
0.07 (L1) + 
0.08 (L10) 
70 30 orange 
 
 Table (8) represent the reactions of 50 ml (0.5 mmol) [PtCl4]2- with 
two mixed ligands, [L2 is one of them] (0.5 mmol of each ligand  dissolved 
in minimum amount of ethanol) in different ratio and temperature. 
Table 8. 
mixed ligands (L2) + L Amount g Temp.;oC 
Time 
(min) Color 
2-(2’-pyridyl)benzimidazole (L2) + 
urea (L7) + Pt2+salt 
0.1 (L2) + 
0.03 (L7) 
70 30 pale green 
2-(2’-pyridyl)benzimidazole (L2) + 
thiourea (L8) + Pt2+salt 
0.1 (L2) + 
0.04 (L8) 
70 30 brown 
2-(2’-pyridyl)benzimidazole (L2) + 
pyridine (L9) + Pt2+salt 
0.1 (L2) + 
0.5 ml (L5) 
70 30 pale green 
2-(2’-pyridyl)benzimidazole (L2) + 
bipyridine (L10) + Pt2+salt 
0.1 (L2) + 
0.08 (L10) 
70 30 pale green 
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 Table (9) represent the reactions of 50 ml (0.5 mmol) [PtCl4]2-  with 
two mixed ligands, [L3 is one of them] (0.5 mmol of each ligand  dissolved in 
minimum amount of ethanol) in different ratio and temperature. 
Table 9. 
mixed ligands (L3) + L Amount g Temp.;oC Time(min) Color 
2-pyrazinecarboxamide  (L3) + 
urea (L7) + Pt2+salt 
0.0.06 (L3) + 
0.03 (L7) 
70 30 dark brown 
2-pyrazinecarboxamide (L3) + 
thiourea (L8) + Pt2+salt 
0.06 (L3) + 
0.04 (L8) 
70 30 dark brown 
2-pyrazinecarboxamide (L3) + 
pyridine (L9) + Pt2+salt 
0.06 (L3) + 
0.5 ml (L5) 
70 30 brown 
2-pyrazinecarboxamide (L3) + 
bipyridine (L10) + Pt2+salt 
0.06 (L3) + 
0.08 (L10) 
70 30 pale brown 
 
 Table (10) represent the reactions of 50 ml (0.5 mmol) [PtCl4]2-  with 
two mixed ligands, [L4 is one of them] (0.5 mmol of each ligand  dissolved in 
minimum amount of ethanol) in different ratio and temperature. 
Table 10. 
mixed ligands (L4) + L Amount g Temp.;oC Time(min) Color 
2-pyrazinecarboxylic acid (L4) + 
2-aminothiazole (L5) + Pt2+salt 
0.07 (L4) + 
0.05 (L5) 
70 30 orange 
2-pyrazinecarboxylic acid (L4) + 
urea (L7) + Pt2+salt 
0.07 (L4) + 
0.03 (L7) 
70 30 reddish brown 
2-pyrazinecarboxylic acid (L4) + 
thiourea (L8) + Pt2+salt 
0.07 (L4) + 
0.04 (L8) 
RT immediately Red 
2-pyrazinecarboxylic acid (L4) + 
pyridine (L9) + Pt2+salt 
0.07 (L4) + 
0.5 ml (L5) 
70 30 orange 
2-pyrazinecarboxylic acid (L4) + 
bipyridine (L10) + Pt2+salt 
0.07 (L4)+ 
0.08 (L10) 
RT immediately orange 
 
 Table (11) represent the reactions of 50 ml (0.5 mmol) [PtCl4]2-  with 
two mixed ligands, [L5  is one of them] (0.5 mmol of each ligand  dissolved 
in minimum amount of ethanol) in different ratio and temperature. 
Table 11. 
mixed ligands (L5) + L Amount g Temp.; oC Time (min) Color 
2-aminothiazole (L5) + 
urea (L7) + Pt2+salt 
0.05 (L5)+ 
0.03 (L7) 
70 30 brown 
2-aminothiazole (L5) + 
thiourea (L8) + Pt2+salt 
0.05 (L5)+ 
0.04 (L8) 
70 30 Reddish-brown 
2-aminothiazole (L5) + 
pyridine (L9) + Pt2+salt 
0.05 (L5)+ 
0.5 ml(L5) 
70 30 brown 
2-aminothiazole (L5) + 
bipyridine (L10) + Pt2+salt 
0.05 (L5)+ 
0.08 (L10) 
70 30 brown 
 
Measurements 
 IR measurements (KBr pellets) were carried out on a Unicam-
Mattson 1000 FT-IR spectrometer. All 1H-NMR measurements were carried 
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out on a Spectrospin-Bruker 300 MHz spectrometer using d6-DMSOas 
solvent. Elemental analyses were performed on Perkin-Elmer 2400 CHN 
elemental analyzer. Mass spectrometry measurements of the solid complexes 
(70 eV, EI) were carried out on a Finnigan MAT SSQ 7000 spectrometer, 
National center for research of Egypt. 
  
Results and discussion  
  Pd2+ and Pt2+complexes derived from binary and ternary were 
synthesized using mono- and bidentate heterocyclic nitrogen donor ligands 
(Scheme 1).All the isolated solid complexes were characterized by elemental 
analyses and spectral (mass spectrometry, IR and NMR) measurements. 
Table 12 shows the color, yield, elemental analyses and mass spectral of the 
complexes. The elemental analyses suggest the molecular formulae of the 
complexes. The binary and ternary complexes show the variations in their 
molecular structures. They varied between mono- and binuclear, and 
covalent and ionic formulae. The values molar conductance in DMSO for the 
Pd2+ and Pt2+ complexes (the 23-36 μS) suggest that the complexes are non 
electrolytes. On the other hand the other complexes show higher molar 
conductance due to their electrolytic nature.  
 The IR spectra of the complexes exhibited the characteristic bands of 
the ligands, υ(OH), υ(NH), υ(C=N) and υ(C=O), with the corresponding 
shifts due to complex formation[28]as shown in Table 13. The υ(C=N) 
vibrations shifted are shifted to higher wave numbers, while the NH band 
shows shifts from higher to lower frequencies relative to those of free ligands 
[30-33]. In case of the complexes derived from PCA and PC ligands the 
(C=O) band is shifted to lower wave numbers confirming the participation of 
the carbonyl group in the coordination [28].Furthermore, the spectra show 
bands in the 651-419 cm-1range attributed to the M-O and M-N bonds [29-
32]. The 1H-NMR spectra of the Pd2+ and Pt2+ complexes show due to the 
protons of NH, NH2, OH, phenyl and pyrazine moieties with the 
corresponding shifts due to complex formation as shown in Table 13 [29-33].  
The results show that the ligands,2-aminobenzimidazole and pyridine, act as 
monodentate through either the pyrazine or pyridyl nitrogen. The other 
ligands, [2-(2'-pyridyl)benzimidazole, 2-pyrazinecarboxamide, 2-
pyrazinecarboxylic acid and bipyridine)], act as bidentate ligands 
coordinating through nitrogen and oxygen donor sites. It is worth to mention 
that the OH group of 2-pyrazinecarboxylic acid coordinates without proton 
displacement in consistent with 1H-NMR data. Therefore, according to the 
elemental analyses and the spectroscopic data, the complexes structures 
(Schemes 2-5) are suggested. 
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Table 12. Elemental analysis and mass spectrometry data of Pd2+and Pt2+complexes. 
 
Complex 
 
Color 
 
Yield 
% 
Elemental analysis 
Found (Calcd.) 
 
Mass spectra 
 C H N M.Wt. m/z 
PdL1 reddish- 
brown 
63 37.85 
(37.90) 
3.25 
(3.18) 
19.11 
(18.94) 
443.61 438 
PtL1 red 76 31.64 
(31.60) 
2.71 
(2.65) 
15.85 
(15.89) 
532.30 536, 533, 
532 
PdL2 yellow 82 38.55 
(38.70) 
2.60 
(2.44) 
11.35 
(11.28) 
372.53 368, 360, 
356 
PtL2 yellow 83 31.28 
(31.30) 
1.74 
(1.97) 
9.05   (9.11) 461.22 464, 462, 
461 
PdL3 brown 61 20.11 
(20.00) 
1.53 
(1.68) 
14.09 
(14.00) 
300.42 278, 279 
PtL3 brown 85 23.48 
(23.50) 
1.86 
(1.97) 
16.49 
(16.41) 
512.22 477, 475, 
468 
PdL4 yellow 75 28.19 
(28.20) 
1.83 
(1.89) 
13.28 
(13.17) 
425.50 398, 383, 
377 
PtL4 orange 87 23.42 
(23.40) 
1.65 
(1.57) 
10.85 
(10.90) 
514.19 512, 508, 
507, 501 
PdL1L9 yellow 58 36.92 
(37.00) 
3.21 
(3.10) 
14.34 
(14.38) 
389.56 392, 391, 38, 
388 
PdL1L10 yellow 62 37.04 
(37.10) 
2.79 
(2.85) 
14.44 
(14.42) 
777.10 649, 648 
PtL1L9 Red 55 24.73 
(24.80) 
2.09 
(2.08) 
8.59 (8.51) 823.35 788, 787, 
785 
PtL1L10 orange 57 30.17 
(30.20) 
2.28 
(2.32) 
11.82 
(11.74) 
954.48 919, 917, 
882 
PdL2L9 yellow 49 45.26 
(45.20) 
3,09 
(3.12) 
12.46 
(12.40) 
451.63 454, 453, 
452, 450 
PdL2L10 buff 53 37.38 
(37.40) 
2.55 
(2.43) 
9.98   (9.92) 706.02 707, 704, 
697 
PtL2L9 pale green 48 25.36 
(25.30) 
1.80 
(1.75) 
7.00(6.95) 806.32 772, 771, 
770 
PtL2L10 pale green 47 29.96 
(29.90) 
1.97 
(1.94) 
7.92 (7.93) 883.40 846, 845, 
840 
PdL3L9 yellow 56 31.69 
(31.70) 
2.68 
(2.66) 
14.79 
(14.76) 
379.52 346, 345, 
343 
PdL3L10 yellow 62 39.44 
(39.50) 
2.84 
(2.87) 
15.27 
(15.34) 
456.61 421, 420, 
419 
PtL3L9 brown 66 25.68 
(25.70) 
2.12 
(2.15) 
12.03 
(12.00) 
468.21 460, 422, 
417, 415 
PtL3L10 pale brown 69 22.18 
(22.20) 
1.68 
(1.62) 
8.68 (8.63) 811.29 552, 550, 
466 
PdL4L9 yellow 46 31.52 
(31.60) 
2.40 
(2.38) 
11.09 
(11.04) 
380.51 347, 345, 
344 
PdL4L10 yellow 48 39.35 
(39.40) 
2.60 
(2.64) 
12.22 
(12.24) 
457.59 422, 420, 
418 
PtL4L9 orange 76 25.53 
(25.60) 
2.01 
(1.93) 
8.99   (8.96) 469.20 424, 396, 
394 
PtL4L10 orange 81 22.21 
(22.18) 
1.55 
(1.49) 
6.95 (6.90) 812.28 615, 524, 
515 
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Table 13. IR and NMR data of the Pd2+and Pt2+ complexes. 
 
Compound 
IR data (cm-1)  
1H-NMR data (ppm) υ(OH) υ(NH) υ(C=N) υ(C=O) 
PdL1 -- 
3309 (m) 
3229 (m) 
3198 (m) 
3155 (m) 
1669 (s) -- 12.47 (bs), 8.52 (bs), 7.38 (m), 7.30(m) 
PtL1 -- 
3304 (m) 
3228 (m) 
3198 (m) 
3157 (m) 
1666 (s) -- 12.54 (bs), 8.50 (bs), 7.36 (m), 7.21(m) 
PdL2 -- 3156 (m) 3084 (m) 1609 (m) -- 
12.65 (bs), 9.48 (d), 8.83 
(d), 8.39 (m), 7.81 (m), 
7.49 (m) 
PtL2 -- 3165 (s) 3108 (m) 1617 (m) -- 
12.68 (bs), 9.46 (d), 8.79 
(d), 8.39 (m), 7.80 (m), 
7.47 (m) 
PdL3 -- 
3304 (m) 
3171 (m) 
3090 (m) 
1652 (s) 1701 (m) 9.20 (d),  8.86 (d), 8.74 (dd), 8.31 (bs), 7.84 (bs) 
PtL3 -- 
3278 (m) 
3189 (m) 
3103 (m) 
3074 (m) 
1692 (sh) 1705 (s) 9.17 (d),  8.88 (d), 8.76 (dd), 8.28 (bs), 7.87 (bs) 
PdL4 3451 (b) -- 1609 (m) 1674 (s) 9.15 (d), 9.13 (s), 8.89 (d), 8.85 (s), 8.83 (d), 8.76 (s) 
PtL4 3468 (b) -- 1627 (w) 1595 (w) 1715 (s) 
9.19 (d), 9.15 (s), 8.86 (d), 
8.83 (s), 8.80 (d), 8.79 (s) 
PdL1L9 -- 
3106 (w) 
3067 (w) 
3041 (w) 
3004 (w) 
1602 (m) 
1570 (w) -- 
12.60 (bs), 8.97 (m), 8.68 
(m), 8.52 (s), 8.13 (m), 
7.32 (m), 7.24 (m) 
PdL1L10 -- 
3108 (w) 
3078 (m) 
3048 (m) 
1682 (w) 
1646 (w) 
1602 (m) 
-- 12.64 (bs), 9.43 (m), 8.56 (m), 8.40 (m), 8.82 (m) 
PtL1L9 -- 
3193 (m) 
3149 (m) 
3071 (m) 
1681 (s) 
1634 (m) -- 
12.62 (bs), 8.93 (m), 8.64 
(m), 8.55 (s), 8.10 (m), 
7.30 (m), 7.19 (m) 
PtL1L10 -- 
3110 (w) 
3085 (w) 
3050 (m) 
1681 (w) 
1606 (m) 
1561 (w) 
-- 12.60 (bs), 9.47 (m), 8.57 (m), 8.40 (m), 8.83 (m) 
PdL2L9 -- 3083 (m) 3054 (m) 
1608 (s) 
1568 (m) -- 
12.67 (bs), 9.43 (d), 8.82 
(d), 8.40 (m), 8.32 (m), 
7.83 (m), 7.45 (m) 
PdL2L10 -- 
3062 (sh) 
3079 (s) 
3046 (s) 
1603 (m) 
1564 (m) -- 
12.63 (bs), 9.49 (d), 8.83 
(d), 8.61 (m), 8.39 (m), 
7.81 (m), 7.86 (m), 7.65 
(m) 
PtL2L9 -- 
3164 (m) 
3101 (m) 
3001 (m) 
1613 (m) 
1564 (sh) -- 
12.64 (bs), 9.45 (d), 8.79 
(d), 8.44 (m), 8.32 (m), 
7.80 (m), 7.47 (m) 
PtL2L10 -- 
3199 (m) 
3112 (m) 
3052 (m) 
1608 (m) 
1562 (sh) -- 
12.63 (bs), 9.47 (d), 8.78 
(d), 8.59 (m), 8.39 (m), 
7.85 (m), 7.82 (m), 7.60 
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(m) 
PdL3L9 -- 
3106 (w) 
3068 (w) 
3040 (w) 
3004 (w) 
1604 (m) 
1572 (w) 1709 (w) 
9.20 (d), 8.90 (m), 8.84 
(d), 8.75 (dd), 8.25 (bs), 
8.08 (m), 7.92 (bs), 7.61 
(m), 7.59 (m) 
PdL3L10 -- 
3107 (w) 
3078 (m) 
3049 (m) 
1602 (m) 
1564 (w) 1704 (m) 
9.53 (d), 9.22 (d), 8.81 
(m), 8.74 (dd), 8.61 (bs), 
8.45 (m), 8.30 (bs), 7.82 
(m) 
PtL3L9 -- 
3108 (m) 
3101 (m) 
3072 (m) 
1655 (m) 
1594 (m) 1703 (vs) 
9.18 (d), 8.91 (m), 8.86 
(d), 8.72 (dd), 8.25 (bs), 
8.04 (m), 7.90 (bs), 7.65 
(m), 7.56 (m) 
PtL3L10 -- 
3209 (m) 
3165 (m) 
3111 (m) 
3072 (m) 
1650 (sh) 
1585 (m) 1692 (s) 
9.50 (d), 9.18 (d), 8.85 
(m), 8.71 (dd), 8.57 (bs), 
8.42 (m), 8.30 (bs), 7.84 
(m) 
PdL4L9 3454 (b) -- 1673 (s) 1598 (m) 1714 (s) 
9.23 (d), 9.14 (s), 8.86 (d), 
8.80 (d), 8.64 (d), 8.04 
(m), 7.63 (m), 7.52 (m) 
PdL4L10 3734 (b) -- 1679 (w) 1602 (m) 1743 (w) 
9.45 (d), 9.20 (s), 8.83 (d), 
8.78 (d), 8.55 (d), 8.48 (s), 
8.40 (m), 7.80 (m) 
PtL4L9 3464 (b) -- 1683 (s) 1596 (m) 
1767 (sh) 
1725 (s) 
9.19 (d), 9.11 (s), 8.86 (d), 
8.82 (d), 8.66 (d), 8.04 
(m), 7.65 (m), 7.55 (m) 
PtL4L10 3464 -- 1605 (sh) 1598 (m) 1713 (s) 
9.48 (d), 9.19 (s), 8.86 (d), 
8.80 (d), 8.58 (d), 8.50 (s), 
8.41 (m), 7.84 (m) 
 
 
Scheme 2. Proposed structures of some binary Pd2+complexes 
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Scheme 3. Proposed structures of some ternary Pd2+complexes. 
 
 
Scheme 4. Suggested structures of some binary Pt2+ complexes. 
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Scheme 5. Suggested structures of some ternary Pt2+complexes. 
 
Applications 
Antibacterial and antifungal activity 
 The free ligands and some of their binary and ternary Pd2+ and Pt2+ 
complexes were screened against the Escherchia coli as Gram-negative 
bacteria and Staphylococcus aureus as Gram-positive bacteria, and the two 
fungus Aspergillus flavus and Candida albicans to assess their potential 
activity relative to the two standards: Tetracycline antibacterial agent and 
Amphotericin B antifungal agent (Figs. 1-3). The data showed that the free 
ligands have the capacity of inhibiting the metabolic growth of the 
investigated bacteria and the fungus to different extents, which may indicate 
broad-spectrum properties. The activity of these compounds may be arising 
from the functional groups moieties. The mode of action may involve the 
formation of hydrogen bonding between the O and N donors and the active 
centers of the cell constituents, resulting in interference with the normal cell 
process [33]. All the tested metal complexes showed activity against both 
Escherchia coli and Staphylococcus aureus. However, although the 
complexes showed promising activities against the two bacteria, their 
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activities were less than the standard Tetracycline. On the other hand, the 
ligands and complexes showed antifungal activities against the tested fungus. 
It is important to point out that some ligands are more toxic against the 
Candida albicans fungus and the Aspergillus flavus fungus compared to the 
standard Amphotericin B antifungal agent. The antibacterial l data revealed 
that some of the Pd2+ and Pt2+ complexes are more bioactive than the free 
ligands. The enhanced activity of the metal complexes may be retained to the 
increase dlipophilic nature of the complexes which arose from the chelation. 
It was also noted that the toxicity of the metal complexes increases on 
increasing the metal ion concentration. This elevation is probably due to 
faster diffusion of the chelates as a whole through the cell membrane. The 
chelated metal may block the enzymatic activity of the cell or it may catalyze 
the toxic reactions among cellular constituents. 
 
Fig 1. In vitro antibacterial and antifungal activities of some of the ligand and some Pd2+ 
complexes. (G-):Gram-negative Escherchia coli bacteria; (G+): Gram-positive 
Staphylococcus aureus bacteria; fungus1: Aspergillus flavus; fungus2: Candida albicans. 
 
Fig 2. In vitro antibacterial and antifungal activities of some of the ligand and some Pd2+ 
complexes. (G-):Gram-negative Escherchia coli bacteria; (G+): Gram-positive 
Staphylococcus aureus bacteria; fungus1: Aspergillus flavus; fungus2: Candida albicans. 
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Fig 3. In vitro antibacterial and antifungal activities of some Pt2+ complexes. 
(G-) :Gram-negative Escherchia coli bacteria; (G+): Gram-positive Staphylococcus aureus 
bacteria; fungus1: Aspergillus flavus; fungus2: Candida albicans. 
Cytotoxicity of some platinum complexes 
 To evaluate the potential usefulness of some of the reported platinum 
complexes (cis-platin analogous) as antitumor agent, three human cell lines 
(two breast cancer cell lines, MCF7 and T47D, and liver carcinoma cell line, 
HepG2) were treated by the PtL1, PtL3L9 and PtL3L10; and compared with 
cis-platin. The complexes showed promising activity against the studied cell 
lines. The IC50 value (the concentration that produce 50% inhibition of cell 
growth) of Pt complexes and cis-platin were determined. The IC50 values of 
the reported platinum complexes were found to be: PtL1 complex: MCF7 
(11.3 µg/ml, 21.6 µM), T47D (19.2 µg/ml, 34.4 µM) and HepG2 (15.9 
µg/ml, 25.7 µM); PtL3L9 complex: MCF7 (3.3 µg/ml, 5.3 µM), T47D (3.9 
µg/ml, 5.7 µM) and HepG2 (3.15 µg/ml, 5.0 µM); PtL3L10 complex: MCF7 
(4.05 µg/ml, 5.1 µM), T47D (4.5 µg/ml, 5.3 µM) and HepG2 (3.75 µg/ml, 
4.9 µM). According to the IC50 values, the PtL1 complex is, thus, considered 
as weak anticancer drug compared to cis-platin (11.9-9.9 µM) [34]. On the 
other hand, the two complexes (PtL3L9 and PtL3L10) are considered as 
strong anticancer drugs compared to cis-platin (11.9-9.9 µM) [34]. However, 
the validity of the complexes as anticancer drugs require further investigation 
such as in vivo study on the effect of the compounds on Ehrlich solid 
carcinoma induced in mice including the study of tumor growth, 
apoptosis/necrosis ratio, hematological profile, liver and kidney functions 
and histological examination of the tumor cells and some organs. 
 
Conclusion 
 Interaction of some mono- and bidentate heterocyclic nitrogen and 
oxygen donor ligands with Pd2+and Pt2+resulted in the formation of a variety 
of binary and ternary complexes. The spectroscopic studies of the complexes 
revealed different structural arrangements. The antibacterial and cytotoxicity 
of some complexes showed promising biological activity. 
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